Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients

Indian Journal of Medical Research

Volumn 125, Issue 2, 2007, Pages 137-142

  Thriveni, K ^a   Deshmane, Vijayalakshmi ^a   Bapsy, P P ^a   Krishnamoorthy, Lakshmi ^a   Ramaswamy, Girija ^a  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

Benign breast disease; Breast cancer; HER 2 neu; Hormone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CARCINOMA; BREAST DISEASE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ONCOGENE NEU; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REFERENCE VALUE;

AGE FACTORS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIA; LOGISTIC MODELS; NEOPLASM STAGING; RECEPTOR, ERBB-2;

EID: 34147148172     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Coussens L, Yang-Feng TL, Liao Y-C, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230 : 1132-9.
2. Slamon DJ, Clark GM. Amplification of C-ERB-B2 and aggressive breast tumors? Science 1988; 240 : 1795-8.
3. De Potter CR. The neu oncogene: more than a prognostic indicator? Hum Pathol 1994; 25 : 1264-8.
4. Kurebayshi J. Biological and clinical significance of HER2 overexpression in breast cancer. Breast Cancer 2001; 8 : 45-51.
5. Brandt-Rauf PW, Pincus MR, Carney WP. The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog 1994; 5 : 313-29.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987; 235 : 177-82.
7. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, et al. Correlation of c-erb B2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48 : 1238-43.
8. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans JO, Dalesio O, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988; 319 : 1239-45.
9. Heintz NH, Leslie KO, Rogers LA, Howard PL. Amplification of the c-erb B-2 oncogene in prognosis of breast adenocarcinoma. Arch Pathol Lab Med 1990; 114 : 160-3.
10. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003; 49 : 1579-98.
11. Duffy MJ. Predictive markers in breast and other cancers: a review. Clin Chem 2005; 51 : 494-503.
12. Brandt-Rauf PW. The c-erb B transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutat Res 1995; 333 : 203-8.
13. Brower ST, Tartter PI, Ahmed S, Brusco CM, Bossolt K, Hayden C, et al. Proliferative indices and oncoprotein expression in benign and malignant breast biopsies. Ann Surg Oncol 1995; 2 : 416-23.
14. Iglehart JD, Kerns BJ, Huper G, Marks JR. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat 1995; 34 : 253-63.
15. Pallud C, Guinebretiere JM, Guepratte S, Hacene K, Neumann R, Carney W, et al. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. Anticancer Res 2005; 25 : 1433-40.
16. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. The Oncologist 2004; 9 (Suppl 3): 20-6.
17. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti- HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic disease. J Clin Oncol 1999; 17 : 2639-48.
18. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 : 783-92.
19. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer. J Clin Oncol 2002; 20 : 719-26.
20. Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA. Serum HER-2/neu and response to the aromatase inhibitor Letrozole versus Tamoxifen. J Clin Oncol 2003; 21 : 1967-72.
21. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Can Res 2000; 6 : 2356-62.
22. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 2004; 2 : 105-16.
23. Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005; 104 : 257-63.
24. Prati R, Apple SK, He J, Gornbein JA, Chang HR. Histopathologic characterisitics prdicting HER-2/neu amplification in breast cancer. Breast J 2005; 11 : 433-9.
25. Neyt M, Albrecht J, Cocquyt V. An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann Oncol 2006; 17 : 381-90.